Polyrizon Ltd. income statement PLRZ

Annual Quarterly

It recorded a net loss of $3.3 million. Diluted earnings per share were $4.90.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
Research and development
2
+299.4%
1
Selling, general and administrative
4
+435.9%
1
Operating income
-6
-380.0%
-1
Net income
-3
-115.9%
-2
Net income to common
3
+107.8%
2
Basic EPS
4.90
-99.4%
805.20
Diluted EPS
4.90
-99.4%
805.20
Weighted average shares, basic
1
+34021.4%
0
Weighted average shares, diluted
1
+34021.4%
0
Other measures
Depreciation and amortization
0
+189.8%
0
EBITDA
-6
-398.9%
-1
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as
PLRZ (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Israel
Headquarters
Ra'Anana
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1893645

Other Surgical & Medical Instruments & Apparatus companies

All 151 Surgical & Medical Instruments & Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.